Semax Peptide – 10mg

Semax (10mg) — Research Compound

At the 10mg concentration, Semax is studied for its dose-dependent impact on neurochemical regulation and its prolonged influence on the central nervous system. This concentration is frequently used in research to observe the saturation limits of BDNF and NGF signaling and the compound’s ability to mitigate significant neurological stressors. Researchers investigate this higher dosage to analyze the depth of its neuroprotective window and its potential to stabilize cognitive markers during periods of high-intensity mental load.

Findings from early-stage clinical trials have reported:

• Dose-dependent increases in the concentration of neurotrophic factors observed across study groups
  
• Enhanced recovery rates of neurological function following ischemic events reported in research cohorts
  
• Marked improvements in information processing and cognitive flexibility noted in experimental models
  
• Sustained modulation of the serotonergic and dopaminergic pathways observed during the study period
  

Researchers study the higher concentration of Semax to explore the duration of its metabolic impact on the brain. By analyzing the interplay between ACTH analogues and neuronal gene expression, it serves as a specialized tool for investigating the management of acute neurological trauma and the preservation of higher-order brain functions. Its multi-receptor profile makes it a primary focus for research into advanced neurotherapy.

Available Formats:
This compound is available as a vial of lyophilised powder, or can be ordered in a disposable pen, a reusable pen, or a cartridge for an existing reusable pen system.

Used solely for in vitro experiments and cannot be:

• Used in clinical trials involving humans
• Administered to humans as part of an experiment or investigation
• Supplied to another party for human investigational use